Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 5/2010

01-09-2010

Multiple Sclerosis and Vitamin D: A Review and Recommendations

Authors: Andrew J. Solomon, Ruth H. Whitham

Published in: Current Neurology and Neuroscience Reports | Issue 5/2010

Login to get access

Abstract

A relationship between vitamin D and several diseases, including multiple sclerosis (MS), has recently received interest in the scientific community. Vitamin D appears to have important actions beyond endocrine function, particularly for the immune system. Risk of development of MS, as well as disease severity, has been associated with vitamin D in a variety of studies. There remains a need for prospective studies to further establish this relationship. Given the current evidence of the potential benefits of vitamin D, it appears to be reasonable and safe to consider vitamin D supplementation at dosing adequate to achieve normal levels in patients with MS and clinically isolated syndrome.
Literature
1.
•• Pierrot-Deseilligny C: Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009, 256:1468–1479. This is an excellent, detailed review article on MS and vitamin D. CrossRefPubMed
2.
Sioka C, Kyritsis AP, Fotopoulos A: Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci 2009, 287:1–6.CrossRefPubMed
3.
Ascherio A, Munger K: Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008, 28:17–28.CrossRefPubMed
4.
5.
Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008, 194:7–17.CrossRefPubMed
6.
7.
Alpert PT, Shaikh U: The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Biol Res Nurs 2007, 9:117–129.CrossRefPubMed
8.
•• Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266–281. This is an excellent general review of vitamin D.CrossRefPubMed
9.
10.
Cherniack EP, Levis S, Troen BR: Hypovitaminosis D: a widespread epidemic. Geriatrics 2008, 63:24–30.PubMed
11.
Adorini L, Penna G: Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4:404–412.CrossRefPubMed
12.
13.
May E, Asadullah K, Zügel U: Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy 2004, 3:377–393.CrossRefPubMed
14.
• Beretich BD, Beretich TM: Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler 2009, 15:891–898. This interesting recent study concerns UV exposure and MS. CrossRefPubMed
15.
• Taylor BV, Lucas RM, Dear K, et al.: Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler 2010, 16:398–405. This interesting recent study concerns latitude and MS. CrossRefPubMed
16.
Alonso A, Hernán MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008, 71:129–135.CrossRefPubMed
17.
18.
Hammond SR, English DR, McLeod JG: The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000, 123:968–974.CrossRefPubMed
19.
Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis—observations from Norway. Neuroepidemiology 2008, 30:140–146.CrossRefPubMed
20.
Sloka JS, Pryse-Phillips WE, Stefanelli M: The relation of ultraviolet radiation and multiple sclerosis in Newfoundland. Can J Neurol Sci 2008, 35:69–74.PubMed
21.
van der Mei IA, Ponsonby AL, Dwyer T, et al.: Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327:316.CrossRefPubMed
22.
Goldacre MJ, Seagroatt V, Yeates D, Acheson ED: Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004, 58:142–144.CrossRefPubMed
23.
Lucas RM, Ponsonby AL, Chapman C, et al.: Association between actinic damage, a biomarker of lifetime sun exposure, and first clinical diagnosis of central nervous system demyelination: the Ausimmune Study. Mult Scler 2008, 14:S29–S293.CrossRef
24.
de Abreu DA, Babron MC, Rebeix I, et al.: Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis. Mult Scler 2009, 15:1146–1152.CrossRef
25.
Koch M, De Keyser J, Tremlett H: Timing of birth and disease progression in multiple sclerosis. Mult Scler 2008, 14:793–798.CrossRefPubMed
26.
Islam T, Gauderman WJ, Cozen W, Mack TM: Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381–388.CrossRefPubMed
27.
Smolders J, Peelen E, Thewissen M, et al.: The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 2009, 8:621–626.CrossRefPubMed
28.
Simon KC, Munger KL, Xing Yang, Ascherio A: Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 2010, 16:133–138.CrossRefPubMed
29.
Munger KL, Zhang SM, O’Reilly E, et al.: Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60–65.PubMed
30.
Munger KL, Levin LI, Hollis BW, et al.: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832–2838.CrossRefPubMed
31.
Hanwell HE, Vieth R, Bar-Or A, et al.: Serum 25-hydroxyvitamin D status as a determinant of multiple sclerosis following an initial demyelinating event in children. Mult Scler 2008, 14: S5–S27.CrossRef
32.
• Mirzaei F, Michels KB, Munger KL, et al.: Gestational vitamin D and the risk of multiple sclerosis in the offspring. AAN Annual Meeting 2010, IN02-2.003. This interesting recent study concerns gestational vitamin D and MS.
33.
van der Mei IA, Ponsonby AL, Dwyer T, et al.: Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007, 254:581–590.CrossRefPubMed
34.
Tremlett H, van der Mei IA, Pittas F, et al.: Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271–279.CrossRefPubMed
35.
Soilu-Hänninen M, Airas L, Mononen I, et al.: 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005, 11:266–271.CrossRefPubMed
36.
Soilu-Hänninen M, Laaksonen M, Laitinen I, et al.: A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:152–157.CrossRefPubMed
37.
• Smolders J, Menheere P, Kessels A, et al.: Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008, 14:1220–1224. This recent study concerns relapses, disability, and vitamin D levels. CrossRefPubMed
38.
• Mowry E, Krupp L, Milazzo M, et al.: Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010, 67:618–624. This recent study concerns relapse rates and vitamin D levels in a pediatric population. PubMed
39.
Royal W 3rd, Mia Y, Li H, Naunton K: Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol 2009, 213:135–141.CrossRefPubMed
40.
Correale J, Ysrraelit MC, Gaitán MI: Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146–1160.CrossRefPubMed
41.
Qin Z, Qin Y, Liu S: Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009, 29:203–210.CrossRefPubMed
42.
Lemire JM, Archer DC: 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991, 87:1103–1107.CrossRefPubMed
43.
Eikelenboom MJ, Killestein J, Kragt JJ, et al.: Gender differences in multiple sclerosis: cytokines and vitamin D. J Neurol Sci 2009, 286:40–42.CrossRefPubMed
44.
• Kimball SM, Ursell MR, O’Connor P, Vieth R: Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007, 86:645–651. This is a safety study of vitamin D in MS. PubMed
45.
46.
Goldberg P, Fleming MC, Picard EH: Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986, 21:193–200.CrossRefPubMed
47.
Nordvik I, Myhr KM, Nyland H, Bjerve KS: Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000, 102:143–149.CrossRefPubMed
48.
Achiron A, Barak Y, Miron S, et al.: Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 2003, 26:53.CrossRefPubMed
49.
Wingerchuk DM, Lesaux J, Rice GP, et al.: A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:1294–1296.CrossRefPubMed
50.
Hiremath GS, Cettomai D, Baynes M, et al.: Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009, 15:735–740.CrossRefPubMed
Metadata
Title
Multiple Sclerosis and Vitamin D: A Review and Recommendations
Authors
Andrew J. Solomon
Ruth H. Whitham
Publication date
01-09-2010
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 5/2010
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-010-0131-5

Other articles of this Issue 5/2010

Current Neurology and Neuroscience Reports 5/2010 Go to the issue

ReviewPaper

An Update on the Neurologic Applications of Botulinum Toxins

ReviewPaper

Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice

ReviewPaper

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

ReviewPaper

Emerging Oral Therapies in Multiple Sclerosis

ReviewPaper

Physical Activity and Mild Cognitive Impairment and Alzheimer’s Disease

Clinical Trial Report

Tarenflurbil in Patients with Mild Alzheimer’s Disease